Astrazeneca PLC (NASDAQ: AZN) suffers from important negative changes in fundamentals: the consensus estimate for December, 2023 decreased significantly, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2024 decreased significantly.
Recent notable negative changes in investment behavior have affected Astrazeneca PLC (NASDAQ: AZN): the stock’s recent price decline challenged its longer term uptrend.
In light of these highly negative signals we are reviewing our current Overall Rating of D. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, AZN is expected to continue to be a major Value Builder.
Astrazeneca has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Astrazeneca has a neutral Appreciation Score of 44 but a poor Power Rating of 24, leading to the Negative Value Trend Rating.
Recent Price Action
Astrazeneca PLC (NASDAQ: AZN) stock declined modestly by -1.5% on 1/17/24. The stock closed at $66.25. Moreover, this decline was accompanied by unusually high trading volume at 160% of normal. The stock has been weak relative to the market over the last nine months and has declined -4.3% during the last week.
Be the first to comment